XM无法为美国居民提供服务。
N
N

Novartis

交易方向

交易者偏好

技术摘要

每小时

市场新闻

Novartis AG <NVS.N> expected to post earnings of $1.96 a share - Earnings Preview

Novartis AG expected to post earnings of $1.96 a share - Earnings Preview Novartis AG NVS.N , NVS is expected to show a rise in quarterly revenue when it reports results on October 29 for the period ending September 30 2024 The Basel Basel-stadt-based company is expected to report a 8.3% increase in revenue to $12.764 billion from $11.78 billion a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
N

Novartis Ribociclib (Kisqali®) Recognized As Category 1 Preferred Breast Cancer Adjuvant Treatment By NCCN

BRIEF-Novartis Ribociclib (Kisqali®) Recognized As Category 1 Preferred Breast Cancer Adjuvant Treatment By NCCN Oct 24 (Reuters) - NOVARTIS AG NOVN.S : RIBOCICLIB (KISQALI®) RECOGNIZED AS CATEGORY 1 PREFERRED BREAST CANCER ADJUVANT TREATMENT BY NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINES®) Source text for Eikon: ID:nGNERj7p9
N

US FDA declines to approve Camurus' rare hormone disorder drug

US FDA declines to approve Camurus' rare hormone disorder drug Oct 22 (Reuters) - The U.S. Food and Drug Administration has declined to approve Camurus' CAMX.ST drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish drugmaker said late Monday. WHY IT'S IMPORTANT The FDA's decision could delay the approval and subsequent launch of the drug, CAM2029, meant to treat patients with acromegaly, which is diagnosed in three to 14 of ev
I
N

Novartis Receives Positive CHMP Opinion For Kisqali To Help Reduce Risk Of Recurrence In People With HR+/Early Breast Cancer

BRIEF-Novartis Receives Positive CHMP Opinion For Kisqali To Help Reduce Risk Of Recurrence In People With HR+/HER2- Early Breast Cancer Oct 18 (Reuters) - Novartis AG NOVN.S : NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR KISQALI® TO HELP REDUCE RISK OF RECURRENCE IN PEOPLE WITH HR+/HER2- EARLY BREAST CANCER Source text for Eikon: ID:nPn6w07lka Fur
N

Novartis Receives Positive CHMP Opinion For Kisqali

BRIEF-Novartis Receives Positive CHMP Opinion For Kisqali Oct 18 (Reuters) - NOVARTIS AG NOVN.S : NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR KISQALI TO HELP REDUCE RISK OF RECURRENCE IN PEOPLE WITH HR+/HER2- EARLY BREAST CANCER CHMP RECOMMENDS MARKETING AUTHORIZATION FOR NOVARTIS' KISQALI KISQALI REDUCES RECURRENCE RISK BY 25% IN PHASE III NATALEE
N

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明